Biosplice is a company that develops therapies using alternative splicing technology to restore health. The company focuses on creating treatments that harness alternative splicing in human DNA to address various medical conditions.

Biosplice

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.  Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing.  Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function.  Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.

Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.  

Learn more at https://www.biosplice.com

CDMRP

Polar Light Ventures

Starling Group

Swicorp

Vickers Venture Partners

Cem Ortabaş

Christian Cadeo

aMoon Fund

Sands Capital Ventures

Eventide

Symbiosis Group

Verition Fund Management

Biosplice Therapeutics

We are pleased to announce our collaboration with Novo Nordisk in the field of diabetes research. This pre-clinical partnership aims to develop first-in-class therapies for diabetes by leveraging our leading position in small-molecule DYRK inhibition.
Learn more about this exciting
collaboration in our latest press release: https://lnkd.in/gw_rUHFQ
#Biotech #Pharma #DiabetesResearch #Collaboration #Innovation #Healthcare #DYRKInhibition #Biosplice #NovoNordisk #FirstInClass #PreclinicalResearch

Arthritis Awareness Month

This Arthritis Awareness Month, we reaffirm our commitment to advancing research and developing innovative treatments to improve the lives of individuals living with knee osteoarthritis.

Arthritis presents significant challenges, impacting mobility, comfort, and overall quality of life. Through our dedication to cutting-edge research, we strive to address not only the symptoms but also the underlying causes of knee osteoarthritis.

Join us in raising awareness and supporting the millions affected by arthritis worldwide.


#ArthritisAwarenessMonth #Biosplice

🧠 Did you know? Alzheimer's disease affects more than memory. Here are 3 things you might not know about Alzheimer's:

1) It impacts multiple cognitive functions beyond memory, including language, decision-making, and even personality.

2) Early detection is crucial. Changes in behavior or cognition could be early signs of Alzheimer's, so it's essential to seek medical attention promptly.

3) Research is advancing. From genetic studies to innovative therapies, scientists are making strides in understanding and treating Alzheimer's.

At Biosplice, we're dedicated to contributing to the fight against Alzheimer's through cutting-edge research and development.  

#Alzheimer #Biosplice

🔍 Today, on International Clinical Trials Day, we pause to recognize the profound impact of clinical research on advancing healthcare worldwide. 💡 Clinical trials are the cornerstone of medical innovation, driving progress and improving patient outcomes. At Biosplice, we're proud to contribute to this important work through our commitment to rigorous research and development. 

#ClinicalTrialsDay #Biosplice

📢 News from Biosplice!

📄 EMJ Rheumatology has selected our presentation as one of the highlights of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO IOF-ESCEO) 2024 in London!

https://lnkd.in/gZQ4SiH3

Read the full article for more insights! #WCO2024 #Osteoarthritis #ClinicalTrials #Lorecivivint #MedicalResearch

🧬World DNA Day
Today, we reflect on the profound impact of genetics on healthcare and the countless possibilities it presents for improving patient outcomes. As we commemorate the discovery of the double helix structure, let's reaffirm our commitment to advancing research and leveraging the potential of genetics research to drive innovation in medicine.

#WorldDNADay #BioSplice #Healthcare #Innovation

🔬 Celebrating International Medical Research Day with Biosplice! 🔬

Today, we recognize the vital role of medical research in shaping the future of healthcare. At Biosplice, we're proud to contribute to health outcomes by focusing on innovative solutions for challenging medical conditions.


Join us in celebrating the incredible impact of medical research on International Medical Research Day!

#InternationalMedicalResearchDay #Biosplice

Biosplice to Present at OARSI 2024 Congress in Vienna! 

We will be showcasing our latest research at the upcoming OARSI 2024 Congress in Vienna, Austria, from April 18th to 21st.

Our presentations include:

- Poster Presentation #299: Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections over 3 Years in Subjects with Severe Knee Osteoarthritis"
- Poster Presentation #297: Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial 


If you're attending OARSI 2024, we invite you to visit our poster presentations and join us in discussions about the latest developments in the field.

#OARSI2024 #Biosplice #Vienna

Exciting news from Biosplice! We're participating in the World Congress of Osteoarthritis (WCO) 2024, taking place from April 11th to 15th in London, UK. 

At this year's conference, we're excited to present our latest research findings:

🔹 Oral Presentation:
"Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections Over 3 Years in Subjects with Severe Knee Osteoarthritis."

🔹 Oral Poster Presentation P674:
"Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial."

These presentations highlight our ongoing commitment to advancing the treatment landscape for osteoarthritis and working to improve patient outcomes. 

#WCO2024 #Biosplice #London

🌍 Today is World Health Day, and at Biosplice, we're dedicated to advancing health and well-being for all. 

With a clinical pipeline focused on osteoarthritis, oncology, and early-stage programs in neurology and other areas of significant unmet medical need, we're committed to making a positive impact on global health.

Join us in prioritizing health and working towards a healthier future for everyone! 

#WorldHealthDay #Biosplice

news impact assignment basic	general
public peers	general	Aug 24, 2024 12:51 PM	02b2d841
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 24, 2024 12:51 PM	168aabe7
translate crunchbase fundingrounds	general
peers	general	Aug 24, 2024 12:51 PM	36ca1c4e
news basic	general	Aug 24, 2024 12:51 PM	015d591f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

BIOS

COM:BIOSPLICE

Biosplice